Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-582949 in moderate to severe plaque psoriasis
NCT00399906Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of BMS-582949 in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Investigator's Global Assessment at 12 weeks. Started Aug 2007; status: completed.
02
Drugs
BMS-582949
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00399906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00399906.